A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Latest Information Update: 08 Mar 2013
At a glance
- Drugs CardiALLO cell therapy (Primary)
- Indications Heart failure; Left ventricular dysfunction
- Focus Adverse reactions
- Acronyms POSEIDON
- 21 Nov 2012 New trial record